Coronavirus Disease 2019 (COVID-19) Study of Hospitalized Patients in Hong Kong

Comprehensive Clinical, Virological, Microbiological, Immunological and Laboratory Monitoring of Patients Hospitalized With Coronavirus Disease 2019 (COVID-19)

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04325919

Enrollment

170

Registered

2020-03-30

Start date

2020-02-24

Completion date

2023-06-17

Last updated

2022-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronavirus Infections

Keywords

SARS-CoV-2, Coronavirus disease 2019

Brief summary

COVID-19 may cause another world-wide epidemic. This study is divided into 2 arms: (1) Prospective longitudinal observational study involving patients with laboratory-confirmed COVID-19 and (2) Retrospective study on patients with laboratory-confirmed COVID-19. Arm 1: We will collect EDTA blood, stool samples, rectal swab, urine, saliva, and specimens from upper respiratory tract (nasopharyngeal aspirate or flocked swab), and lower respiratory tract (sputum or tracheal aspirate) on daily, alternate day, or weekly basis as appropriate. Arm 2: The remainder of specimens that were submitted for laboratory investigation as part of clinical management will be retrieved. Those specimens will only be used after all clinically indicated testing and confirmation procedures have been completed. Assistance from the Public Health Laboratory Service, Department of Health, will be invited to retrieve samples as well as participate in this study. Patients hospitalized for pneumonia in medical wards and ICU at the Prince of Wales Hospital tested negative for COVID-19 will be recruited as controls. Understanding the clinical, virological, microbiological and immunological profiles of this infection is urgently needed to facilitate its management and control.

Interventions

OTHERNo intervention

No intervention

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Case are adults age ≥ 18 years old admitted to hospital with laboratory confirmed COVID-19 * Controls are patients admitted for community-acquired pneumonia

Exclusion criteria

* Patients who refuse to consent for study

Design outcomes

Primary

Measure	Time frame	Description
Clinical	6 months	Patients' treatment and management during hospitalization.
Virological	6 months	Serial viral load changes during hospitalization.
Microbiological	6 months	Alterations in fecal microbiota composition (including virome, bacteria and fungi) in COVID-19 patients compared with healthy controls.

Countries

Hong Kong

Contacts

Primary ContactPaul CHAN

paulkschan@cuhk.edu.hk+852 35053339

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026